Skip to content
CancerIndex

Publication

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.

Authors not recorded

J Clin Oncol2004PMID 14726504stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
14726504
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
CEBPA Mutation1
(prognostic)Acute Myeloid LeukemiaCURATED_BROADERPrognosticBSupports Better Outcome3accepted
EID168

Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/… (full text at CIViC)

PMID 14726504 · Fröhling et al., 2004 · Open in CIViC

civic
CEBPA N-TERMINAL FRAME SHIFT1
(prognostic)Acute Myeloid LeukemiaCURATED_BROADERPrognosticBSupports Better Outcome3accepted
EID169

Remission duration was significantly longer in younger (16-60), cytogenetically normal AML patients with CEBPA

PMID 14726504 · Fröhling et al., 2004 · Open in CIViC

civic
FLT3 Mutation1
(prognostic)Acute Myeloid LeukemiaCURATED_BROADERPrognosticBDoes Not Support N/A2accepted
EID156

FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 muta… (full text at CIViC)

PMID 14726504 · Fröhling et al., 2004 · Open in CIViC

civic